Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

SET/TAF-I anticorps (N-Term)

SET Reactivité: Humain WB, IHC (p) Hôte: Lapin Polyclonal unconjugated
N° du produit ABIN5535669
  • Antigène Voir toutes SET/TAF-I (SET) Anticorps
    SET/TAF-I (SET) (SET Nuclear Oncogene (SET))
    Épitope
    • 10
    • 7
    • 5
    • 5
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 47-75, N-Term
    Reactivité
    • 71
    • 33
    • 32
    • 6
    • 5
    • 4
    • 4
    • 3
    • 3
    • 3
    • 2
    • 1
    • 1
    Humain
    Hôte
    • 66
    • 3
    • 2
    Lapin
    Clonalité
    • 57
    • 13
    Polyclonal
    Conjugué
    • 34
    • 6
    • 5
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp SET/TAF-I est non-conjugé
    Application
    • 52
    • 27
    • 23
    • 14
    • 13
    • 10
    • 7
    • 5
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
    Purification
    This antibody is purified through a protein A column, followed by peptide affinity purification.
    Immunogène
    This SET antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 47-75 amino acids from the N-terminal region of human SET.
    Isotype
    Ig Fraction
    Top Product
    Discover our top product SET Anticorps primaire
  • Indications d'application
    For WB starting dilution is: 1:1000

    For IHC-P starting dilution is: 1:10~50
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    0.5 mg/mL
    Buffer
    Supplied in PBS with 0.09 % (W/V) sodium azide.
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C,-20 °C
    Stockage commentaire
    Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
  • Antigène
    SET/TAF-I (SET) (SET Nuclear Oncogene (SET))
    Autre désignation
    SET (SET Produits)
    Synonymes
    anticorps 2PP2A, anticorps I2PP2A, anticorps IGAAD, anticorps IPP2A2, anticorps PHAPII, anticorps TAF-I, anticorps TAF-IBETA, anticorps 2610030F17Rik, anticorps 5730420M11Rik, anticorps AA407739, anticorps I-2PP2A, anticorps StF-IT-1, anticorps 2pp2a, anticorps i2pp2a, anticorps igaad, anticorps ipp2a2, anticorps phapii, anticorps set, anticorps set-a, anticorps set-b, anticorps taf-ibeta, anticorps wu:fb30g11, anticorps wu:fd16c08, anticorps SET nuclear proto-oncogene, anticorps SET nuclear oncogene, anticorps SET translocation, anticorps SET nuclear proto-oncogene L homeolog, anticorps SET nuclear proto-oncogene b, anticorps SET, anticorps Set, anticorps LOC403555, anticorps set.L, anticorps setb
    Sujet
    Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone binding. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T-lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins, however, isoform 2 specific activity is higher.
    Poids moléculaire
    33 kDa
    ID gène
    6418
    UniProt
    Q01105
    Pathways
    Apoptose
Vous êtes ici:
Support technique